| News Updates |
 |
Drug Regimen For HIV Shows Non-Inferiority to Antiretroviral Therapies
Drug Topics | March 14, 2025
|
|
Merck releases positive phase 3 data on daily oral HIV drug
MSN | March 13, 2025
|
|
What's happening with the anti-HIV program PEPFAR? It depends whom you ask
NPR | February 13, 2025
|
|
US spells out life-saving HIV treatment that can continue during aid pause
Reuters | February 1, 2025
|
|
What to Do if You Can’t Get Your HIV Medication Costs Covered
The Body | January 29, 2025
|
|
Combination of Dolutegravir, Lamivudine Effective in People Living With HIV
American Journal of Managed Care | January 22, 2025
|
|
NIAID Study Describes Successful Treatment Regimen for Person with Multidrug-Resistant HIV
NIH | January 16, 2025
|
|
DoxyPEP Tied to Decreases in Sexually Transmitted Infections
Health Day | January 7, 2025
|
|
WHO to Develop Lenacapavir and HIV Testing Guidelines
Managed Healthcare | January 7, 2025
|
|
Twice-Yearly Lenacapavir Could Support HIV Prevention in Vulnerable Populations
JAMA | January 3, 2025
|
|
Anticipated facilitators and barriers for long-acting injectable antiretrovirals as HIV treatment and prevention in Vietnam: a qualitative study among...
BMC Infectious Diseases - BioMed Central | December 25, 2024
|
|
Doravirine/Islatravir HIV Treatment Combo Looks Good in Late-Stage Trials
POZ Magazine | December 25, 2024
|
|
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Twice-Yearly Lenacapavir for HIV Prevention
Gilead | December 19, 2024
|
|
Gilead plans to halt free access to an HIV drug, worrying patient advocates
STAT | December 19, 2024
|
|
Global leaders in the HIV response call for access to long-acting medicines
UNAIDS | December 10, 2024
|
|
Weight Gain While Treating HIV: Why It Happens
WebMD | November 14, 2024
|
|
Code Pharma’s Gammora® Demonstrates Highly Favorable Outcomes Toward a Potential Cure for HIV
BusinessWire | November 12, 2024
|
|
Gilead and Merck Report Successful Phase 2 Results for Investigational Once-Weekly HIV Treatment
Contagion Live | November 11, 2024
|
|
Curr Opin HIV AIDS | 2024 Nov 5
|
|
Shaping the Next Era of HIV Therapeutics and Care
POZ Magazine | October 30, 2024
|
|
FDA Approves New UTI Antibiotic
Conexiant | October, 25, 2024
|
|
Updated Coverage Guidance Under the Affordable Care Act: Long-Acting PrEP
HIV.gov | October 24, 2024
|
|
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir...
BioSpace | October 21, 2024
|
|
Biden Sides with Insurers, Shifting More Costs to Patients
ADAP | October 17, 2024
|
|
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
ViiV Healthcare | October 7, 2024
|
|
Biopharma firm Gilead announces lenacapavir licensing for HIV treatment
The Indian Express | October 4, 2024
|
|
Gilead Signs Voluntary Licensing Agreements for Lenacapavir PrEP
POZ | October 4, 2024
|
|
HIV prevention: why a new injectable drug could be such a breakthrough
The Conversation | October 3, 2024
|
|
A Promising Injectable for HIV Prevention
Yale School of Medicine | October 3, 2024
|
| |
|
